P390Evaluation of biosimilar insulin use: Perception and experience (INSPIRE)R DONNELLY, M Burke, L Haire, S Baxter and W MundayDiabetes Team, South Eastern Health & Social Care Trust, Dundonald, UKBackground: Abasaglar, the first UK licensed biosimilar insulin glargine, has been shown not to have any clinically significant differences from Lantus in terms of quality, safety and efficacy. Future diabetes management will see an expansion in the availability of biosimilar insulin and has the potential to offer the National Health Service considerable cost savings. Patient and clinical staff perspectives may be an important determinant in the success or failure of this exciting development in diabetes care.Aims: The aim of this evaluation was to explore perceptions of Abasaglar prescribing within the South Eastern Health and Social Care Trust diabetes team. The evaluation also sought to explore the experiences of patients prescribed Abasaglar compared to those prescribed Lantus.Methods: Clinical staff were made aware of the rationale for the service evaluation. Education sessions were provided and staff were invited to consider prescribing Abasaglar according to current National Institute for Health and Care Excellence (NICE) guidelines. Questionnaires were circulated at baseline and nine months. Perspectives assessed; staff insight, viewpoint, attitudes and barriers to prescribing biosimilar
Diabetic Medicine – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera